<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901484</url>
  </required_header>
  <id_info>
    <org_study_id>2012162</org_study_id>
    <nct_id>NCT01901484</nct_id>
  </id_info>
  <brief_title>Schistosoma Mansoni Morbidity in Children Aged 1-5 Years</brief_title>
  <official_title>Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is about intestinal schistosomiasis, commonly known as bilharzia, in children aged
      1-5 years along Lake Victoria shoreline.The children will be screened for S. mansoni and the
      effects of the disease will be assessed.Children found positive with S. mansoni will be
      treated with praziquantel and followed up for a year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study has three phases: in the first phase (Phase I) a baseline pretreatment
      schistosomiasis morbidity assessment of children aged 1-5 years will take place. The
      Kato-Katz technique will be used to detect and enumerate S. mansoni eggs in faecal samples
      from each participating child. Communities with the highest S. mansoni prevalence and
      intensity will be chosen and included in the study. In the second phase (Phase II) the S.
      mansoni positive children will be divided randomly into two intervention groups, single and
      double dose praziquantel treatment arms. Abdominal ultrasound will be combined with clinical
      examination to accurately identify hepatosplenomegaly. The sizes of both the liver and spleen
      will be examined. Anthropometric measurements and Hb for each child will also be recorded. In
      the last phase (Phase III), the effect of praziquantel on S. mansoni morbidity will be
      evaluated in all the treated children aged 1-5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence/absence of organomegaly at Day 0 and 8 months follow-up visits</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cure rate at 30 days after treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Intestinal Schistosomiasis</condition>
  <arm_group>
    <arm_group_label>Drug: Praziquantel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Praziquantel 40mg/Kg - single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Praziquantel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>double dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Praziquantel</intervention_name>
    <description>All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.</description>
    <arm_group_label>Drug: Praziquantel</arm_group_label>
    <arm_group_label>Praziquantel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1-5 years

        Exclusion Criteria:

        &lt;1-5&gt; years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen Nalugwa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHDC-Makerere University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annette Olsen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edridah Muheki, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ministry of Health, Vector Control Division</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fred Nuwaha, PhD</last_name>
    <role>Study Director</role>
    <affiliation>School of Public Health, Makerere University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Child Health &amp; Development Centre, College of Health Sciences , Makerere University</name>
      <address>
        <city>Kampala</city>
        <zip>6717</zip>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makerere University</investigator_affiliation>
    <investigator_full_name>Allen Nalugwa</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Schistosoma mansoni</keyword>
  <keyword>morbidity</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schistosomiasis</mesh_term>
    <mesh_term>Schistosomiasis mansoni</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

